186 related articles for article (PubMed ID: 37525498)
1. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
[TBL] [Abstract][Full Text] [Related]
2. PRKDC-Mediated NHEJ May Play a Crucial Role in Aneuploidy of Chromosome 8-Driven Progression of Ovarian Cancer.
Luan W; Cheng H; Xie H; Liu H; Wang Y; Wang S; Ye X; Zhu H; Tang F; Li Y; Chang X
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732044
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
5. Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.
Ballabio S; Craparotta I; Paracchini L; Mannarino L; Corso S; Pezzotta MG; Vescio M; Fruscio R; Romualdi C; Dainese E; Ceppi L; Calura E; Pileggi S; Siravegna G; Pattini L; Martini P; Delle Marchette M; Mangioni C; Ardizzoia A; Pellegrino A; Landoni F; D'Incalci M; Beltrame L; Marchini S
Int J Cancer; 2019 Nov; 145(10):2670-2681. PubMed ID: 30892690
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data.
Siavoshi A; Taghizadeh M; Dookhe E; Piran M
Genomics; 2022 Jan; 114(1):161-170. PubMed ID: 34839022
[TBL] [Abstract][Full Text] [Related]
7. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma.
Yamamoto A; Kurata M; Yamamoto K; Nogawa D; Inoue M; Ishibashi S; Ikeda M; Miyasaka N; Kitagawa M
Pathol Res Pract; 2020 Nov; 216(11):153175. PubMed ID: 32841774
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.
Reid BM; Permuth JB; Chen YA; Fridley BL; Iversen ES; Chen Z; Jim H; Vierkant RA; Cunningham JM; Barnholtz-Sloan JS; Narod S; Risch H; Schildkraut JM; Goode EL; Monteiro AN; Sellers TA
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1117-1126. PubMed ID: 30948450
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
Li L; Bai H; Yang J; Cao D; Shen K
Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
[TBL] [Abstract][Full Text] [Related]
10. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract][Full Text] [Related]
11. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
DeVries AA; Dennis J; Tyrer JP; Peng PC; Coetzee SG; Reyes AL; Plummer JT; Davis BD; Chen SS; Dezem FS; Aben KKH; Anton-Culver H; Antonenkova NN; Beckmann MW; Beeghly-Fadiel A; Berchuck A; Bogdanova NV; Bogdanova-Markov N; Brenton JD; Butzow R; Campbell I; Chang-Claude J; Chenevix-Trench G; Cook LS; DeFazio A; Doherty JA; Dörk T; Eccles DM; Eliassen AH; Fasching PA; Fortner RT; Giles GG; Goode EL; Goodman MT; Gronwald J; ; ; Håkansson N; Hildebrandt MAT; Huff C; Huntsman DG; Jensen A; Kar S; Karlan BY; Khusnutdinova EK; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Labrie M; Lambrechts D; Le ND; Lubiński J; May T; Menon U; Milne RL; Modugno F; Monteiro AN; Moysich KB; Odunsi K; Olsson H; Pearce CL; Pejovic T; Ramus SJ; Riboli E; Riggan MJ; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Sieh W; Song H; Sutphen R; Terry KL; Thompson PJ; Titus L; Tworoger SS; Van Nieuwenhuysen E; Edwards DV; Webb PM; Wentzensen N; Whittemore AS; Wolk A; Wu AH; Ziogas A; Freedman ML; Lawrenson K; Pharoah PDP; Easton DF; Gayther SA; Jones MR
J Natl Cancer Inst; 2022 Nov; 114(11):1533-1544. PubMed ID: 36210504
[TBL] [Abstract][Full Text] [Related]
12. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
14. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
15. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
16. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2.
Li J; Liang H; Xiao W; Wei P; Chen H; Chen Z; Yang R; Jiang H; Zhang Y
BMC Cancer; 2023 Apr; 23(1):321. PubMed ID: 37024829
[TBL] [Abstract][Full Text] [Related]
18. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.
Guerrero K; Wang Z; Bachvarova M; Gregoire J; Renaud MC; Plante M; Bachvarov D
Gynecol Oncol; 2012 Jun; 125(3):720-6. PubMed ID: 22446619
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a novel long non-coding RNA (LINC01465) in ovarian cancer.
Malgundkar SH; Hassan NA; Al Badi H; Gupta I; Burney IA; Al Hashami Z; Al Barwani H; Al Riyami H; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
Hum Cell; 2023 Mar; 36(2):762-774. PubMed ID: 36513868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
